Remifentanil
رمیفنتانیل
🧠 Nervous SystemUltra-short-acting opioid
Market / country: 🇺🇸 USA
Ultiva (US)
🧮 Dose calculator
General anaesthesia and premedication (adjunct) · Regimen source: FDA Ultiva · 2.2, Table 1
- • Induction: 0.5–1 mcg/kg/min; initial bolus 1 mcg/kg over 30–60 s. With nitrous oxide 0.4 mcg/kg/min. Over 65: halve the starting dose. Obesity: ideal body weight. Infusion device only; not adequate as sole anaesthetic. FDA Ultiva · 2.2, Table 1FDA Ultiva · 2.6FDA Ultiva · 2.9FDA Ultiva · 2.1
- • Only by personnel trained in anaesthesia, with airway, ventilation and resuscitation equipment at hand. FDA Ultiva · 2.1
Enter age and weight.
🛡️ Safety & information
Contraindications
- ⛔ Epidural or intrathecal use (contains glycine); hypersensitivity to remifentanil. FDA Ultiva · 4
Warnings
- • Boxed warning: addiction and misuse; life-threatening respiratory depression; risks with benzodiazepines and other CNS depressants. FDA Ultiva · Boxed Warning
- • Skeletal muscle rigidity; bradycardia and hypotension; rapid offset; opioid-induced hyperalgesia. FDA Ultiva · 5
Formulations
- Diluted 50 mcg/mL (1 mg in 20 mL) — injection 🇺🇸 USA FDA Ultiva · 2, Table 5
- 1 mg vial (dilute before use) — powder for injection 🇺🇸 USA FDA Ultiva · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Ultiva · 8.1
“Risk Summary Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ultiva · 8.2
“Because fentanyl analogs are excreted in human milk, caution should be exercised when ULTIVA is administered to a nursing woman.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ultiva · 8.4
“The efficacy and safety of ULTIVA as an analgesic agent for use in the maintenance of general anesthesia in outpatient and inpatient pediatric surgery have been established in controlled clinical studies in pediatric patients from birth to 12 years [see Clinical Studies (14.4) ] .”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ultiva · 8.5
“Titrate the dosage of ULTIVA slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.2) ] .”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)NDA020630
- DailyMed (FDA label)FDA Ultiva
- MedlinePlus (NIH)❌ None
- WHO ATC/DDDN01AH06
- Darooyab (Iran)Remifentanil
🇮🇷 Registered in Iran Darooyab · G-179/Remifentanil
Dosage forms with Iranian generic codes, per Darooyab.
- 02182 · REMIFENTANIL HCL 1MG VIAL · ویال رمیفنتانیل هیدروکلراید ۱ میلیگرم
- 02183 · REMIFENTANIL HCL 2MG VIAL · ویال رمیفنتانیل هیدروکلراید ۲ میلیگرم
- 02184 · REMIFENTANIL HCL 5MG VIAL · ویال رمیفنتانیل هیدروکلراید ۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ultiva · 2, Table 5FDA Ultiva · 3FDA Ultiva · 2.2, Table 1FDA Ultiva · 2.6FDA Ultiva · 2.9FDA Ultiva · 2.1FDA Ultiva · 2.3FDA Ultiva · 2.5FDA Ultiva · 4FDA Ultiva · Boxed WarningFDA Ultiva · 5FDA Ultiva · SPL approval / marketing categoryFDA Ultiva · 8.1FDA Ultiva · 8.2FDA Ultiva · 8.4FDA Ultiva · 8.5
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-179/Remifentanil
- Clinical review⚠ Unverified